

Michel M Attal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2460043/publications.pdf>

Version: 2024-02-01

269
papers

28,931
citations

6840

81
h-index

6024

165
g-index

271
all docs

271
docs citations

271
times ranked

13633
citing authors

#	ARTICLE	IF	CITATIONS
1	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. <i>Blood</i> , 2022, 139, 2747-2757.	0.6	16
2	Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1859-1867.	1.9	5
3	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. <i>Blood</i> , 2021, 138, 113-121.	0.6	22
4	Anti- μ B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
5	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , 2020, 12, 163.	1.8	9
6	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , 2020, 105, e480-483.	1.7	42
7	Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells. <i>Stem Cells International</i> , 2020, 2020, 1-9.	1.2	5
8	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1323-1333.	0.6	18
9	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
10	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naïve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.	2.2	168
11	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
12	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 29-38.	6.3	665
13	Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4224-4230.	3.2	12
14	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	0.8	111
15	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	2.8	38
16	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e228-e237.	0.2	11
17	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. <i>Leukemia</i> , 2019, 33, 313-318.	3.3	17
18	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. <i>Annals of Hematology</i> , 2018, 97, 831-837.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. <i>Future Oncology</i> , 2018, 14, 1035-1047.	1.1	65
20	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018, 32, 2626-2635.	3.3	48
21	DKK1 and sclerostin are early markers of relapse in multiple myeloma. <i>Bone</i> , 2018, 113, 114-117.	1.4	15
22	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	0.6	216
23	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). <i>Blood</i> , 2018, 132, 2778-2780.	0.6	18
24	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2018, 132, 2555-2563.	0.6	54
25	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	0.6	301
26	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	3.3	53
27	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of \hat{P}^{SUVmax} in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , 2018, 24, 5219-5224.	3.2	24
28	One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 704.	2.2	15
29	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
30	Multiple myeloma clonal evolution in homogeneously treated patients. <i>Leukemia</i> , 2018, 32, 2636-2647.	3.3	94
31	Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 190-190.	0.6	1
32	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
33	Genomics of Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 963-967.	0.8	85
34	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
35	Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , 2017, 7, 9257.	1.6	20
36	Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM) Tj ETQq0 0,0,rgBT /Oyerlock 10	0,2	1

#	ARTICLE	IF	CITATIONS
37	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	0.9	10
38	Improved outcome for AML patients over the years 2000â€“2014. <i>Blood Cancer Journal</i> , 2017, 7, 635.	2.8	63
39	How I treat first relapse of myeloma. <i>Blood</i> , 2017, 130, 963-973.	0.6	58
40	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	0.6	102
41	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
42	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	0.8	247
43	Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. <i>British Journal of Haematology</i> , 2016, 174, 868-875.	1.2	5
44	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. <i>Blood</i> , 2016, 128, 2941-2948.	0.6	58
45	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355.	3.2	38
46	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. <i>Haematologica</i> , 2016, 101, 356-362.	1.7	25
47	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
48	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , 2016, 127, 2569-2574.	0.6	224
49	Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response. <i>Medicine (United States)</i> , 2016, 95, e5356.	0.4	6
50	Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. <i>Annals of Oncology</i> , 2016, 27, 902-907.	0.6	10
51	Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du My�lome (IFM) Krd Phase II Study. <i>Blood</i> , 2016, 128, 1142-1142.	0.6	36
52	Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. <i>Blood</i> , 2016, 128, 2138-2138.	0.6	6
53	A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 238-238.	0.6	2
54	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	0.6	11

#	ARTICLE	IF	CITATIONS
55	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. <i>Blood</i> , 2016, 128, 356-356.	0.6	1
56	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du My��Lome (IFM). <i>Blood</i> , 2016, 128, 674-674.	0.6	16
57	Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM. <i>Blood</i> , 2016, 128, 3569-3569.	0.6	0
58	IFM2012-03. <i>Blood</i> , 2016, 128, 2128-2128.	0.6	0
59	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. <i>Blood</i> , 2015, 126, 2713-2719.	0.6	92
60	Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood</i> , 2015, 125, 1411-1417.	0.6	91
61	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
62	Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?. <i>Bone Marrow Transplantation</i> , 2015, 50, 1024-1029.	1.3	31
63	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	0.6	47
64	Frontline therapy of multiple myeloma. <i>Blood</i> , 2015, 125, 3076-3084.	0.6	244
65	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015, 125, 2095-2100.	0.6	82
66	Bortezomib��thalidomide��dexamethasone versus bortezomib��cyclophosphamide��dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 168, 605-606.	1.2	6
67	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood��and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
68	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. <i>Bone Marrow Transplantation</i> , 2015, 50, 209-215.	1.3	108
69	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 191-191.	0.6	50
70	Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma. <i>Blood</i> , 2015, 126, 21-21.	0.6	8
71	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015, 126, 391-391.	0.6	99
72	Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial. <i>Blood</i> , 2015, 126, 393-393.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	0.6	20
74	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	0.6	15
75	Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8578-8578.	0.8	0
76	Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 4212-4212.	0.6	0
77	Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. <i>Journal of Cancer</i> , 2014, 5, 248-252.	1.2	9
78	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 389-396.	1.3	92
79	All transplantation-eligible patients with myeloma should receive ASCT in first response. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 250-254.	0.9	13
80	Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. <i>Leukemia</i> , 2014, 28, 675-679.	3.3	91
81	The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. <i>Expert Review of Hematology</i> , 2014, 7, 55-66.	1.0	17
82	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
83	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2014, 49, 671-678.	1.3	18
84	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2014, 49, 950-954.	1.3	5
85	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	13.9	697
86	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du My�lome. <i>Journal of Clinical Oncology</i> , 2014, 32, 2712-2717.	0.8	243
87	Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation. <i>Immunobiology</i> , 2014, 219, 611-618.	0.8	8
88	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression�Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	0.8	150
89	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , 2014, 99, 1236-1238.	1.7	35
90	Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial. <i>Blood</i> , 2014, 124, 180-180.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment. <i>Blood</i> , 2014, 124, 2005-2005.	0.6	1
92	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014, 124, 2036-2036.	0.6	1
93	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	0.6	25
94	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8592-8592.	0.8	0
95	A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus. <i>Blood</i> , 2014, 124, 2057-2057.	0.6	0
96	Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma. <i>Blood</i> , 2014, 124, 3466-3466.	0.6	1
97	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSC, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	0.6	2
98	Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy. <i>Blood</i> , 2014, 124, 3396-3396.	0.6	0
99	Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. <i>Leukemia</i> , 2013, 27, 2242-2244.	3.3	52
100	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. <i>Experimental Hematology</i> , 2013, 41, 1008-1015.	0.2	19
101	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 3279-3287.	0.8	238
102	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	3.3	174
103	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1409-1414.	1.3	63
104	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 4634-4637.	3.2	12
105	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du MyÃ©lome Experience. <i>Journal of Clinical Oncology</i> , 2013, 31, 2806-2809.	0.8	103
106	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-â€œrefractory multiple myeloma: Intergroupe Francophone du MyÃ©lome 2009-02. <i>Blood</i> , 2013, 121, 1968-1975.	0.6	201
107	Prognostic utility of intact immunoglobulin Igâ€² ^{Î²} /Igâ€² ^{Î³} ratios in multiple myeloma patients. <i>Leukemia</i> , 2013, 27, 202-207.	3.3	69
108	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2618-2626.	0.6	100

#	ARTICLE	IF	CITATIONS
109	Myeloma: a subclonal disease?. Hematologie, 2013, 19, 383-387.	0.0	0
110	Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES. Blood, 2013, 122, 1933-1933.	0.6	6
111	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq1 1 0.784314 rgBT /Ove (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood, 2013, 122, 2-2.	0.6	39
112	Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3106-3106.	0.6	1
113	Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial. Blood, 2013, 122, 406-406.	0.6	41
114	Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14). Blood, 2013, 122, 689-689.	0.6	9
115	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	0.6	56
116	Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd. Blood, 2013, 122, 3221-3221.	0.6	0
117	Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial. Blood, 2013, 122, 3312-3312.	0.6	0
118	Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution. Blood, 2013, 122, 399-399.	0.6	0
119	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. Journal of Clinical Oncology, 2012, 30, 1949-1952.	0.8	198
120	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1782-1791.	13.9	1,022
121	IMWG consensus on maintenance therapy in multiple myeloma. Blood, 2012, 119, 3003-3015.	0.6	178
122	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based Aon AData from the European Blood and Marrow ATransplantation Registry. Biology of Blood and Marrow Transplantation, 2012, 18, 788-793.	2.0	102
123	Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 418-422.	0.2	4
124	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research, 2012, 72, 1395-1406.	0.4	90
125	Growth factor associated graft versus host disease and mortality 10 years after allogeneic bone marrow transplantation. British Journal of Haematology, 2012, 157, 220-229.	1.2	5
126	Dual energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma. European Journal of Haematology, 2012, 88, 388-395.	1.1	12

#	ARTICLE	IF	CITATIONS
127	Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study. Blood, 2012, 120, 196-196.	0.6	2
128	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. Blood, 2012, 120, 749-749.	0.6	8
129	1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients. Blood, 2012, 120, 933-933.	0.6	13
130	Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8009-8009.	0.8	10
131	Maintenance Therapy for Myeloma: How Much, How Long, and at What Cost?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 515-522.	1.8	5
132	Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide. Blood, 2012, 120, 4075-4075.	0.6	0
133	Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease.. Blood, 2012, 120, 2961-2961.	0.6	0
134	Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).. Blood, 2012, 120, 3096-3096.	0.6	0
135	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. Blood, 2012, 120, 1975-1975.	0.6	5
136	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. Journal of Clinical Oncology, 2011, 29, 1898-1906.	0.8	126
137	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood, 2011, 117, 2009-2011.	0.6	115
138	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 2011, 117, 3041-3044.	0.6	109
139	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	0.6	282
140	Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 2011, 118, 5752-5758.	0.6	275
141	Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. Clinical Cancer Research, 2011, 17, 1253-1263.	3.2	72
142	Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients. Recent Results in Cancer Research, 2011, 183, 189-206.	1.8	20
143	Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program. Blood, 2011, 118, 1872-1872.	0.6	13
144	High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02. Blood, 2011, 118, 812-812.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1816-1816.	0.6	0
146	PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients. <i>Blood</i> , 2011, 118, 1612-1612.	0.6	0
147	CR As Major End-Point After Consolidation for Multiple Myeloma Patients Eligible to High Dose Therapy. <i>Blood</i> , 2011, 118, 1858-1858.	0.6	0
148	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010, 95, 1973-1976.	1.7	124
149	Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2010, 95, 1738-1744.	1.7	109
150	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). <i>Blood</i> , 2010, 115, 32-37.	0.6	152
151	Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. <i>Blood</i> , 2010, 116, 3157-3162.	0.6	49
152	DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in Multiple Myeloma. <i>European Journal of Haematology</i> , 2010, 84, 276-277.	1.1	9
153	Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2010, 85, 65-7.	1.1	13
154	Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, e88-e90.	0.4	5
155	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	0.8	142
156	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). <i>Journal of Clinical Oncology</i> , 2010, 28, 4630-4634.	0.8	383
157	Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. <i>Haematologica</i> , 2010, 95, 996-1003.	1.7	38
158	Reply to J.C. Regeling et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e744-e745.	0.8	0
159	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. <i>Journal of Clinical Oncology</i> , 2010, 28, 1209-1214.	0.8	144
160	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4621-4629.	0.8	512
161	Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study. <i>Blood</i> , 2010, 116, 1944-1944.	0.6	8
162	Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen. <i>Blood</i> , 2010, 116, 3041-3041.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.. Blood, 2010, 116, 310-310.	0.6	50
164	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2010, 116, 363-363.	0.6	1
165	Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. Blood, 2010, 116, 624-624.	0.6	14
166	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma?: a Retrospective Study From the Lymphoma Working Party of the EBMT. Blood, 2010, 116, 688-688.	0.6	14
167	Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02. Blood, 2010, 116, 859-859.	0.6	5
168	Comparison of Stromal Cells of Adipose Tissue From Multiple Myeloma Patients and Healthy Donors. Blood, 2010, 116, 2979-2979.	0.6	0
169	Growth Differentiation Factor 15 Is a Survival Factor for multiple myeloma cells and its plasma Concentration In Patients Is Related to Reduced Survival. Blood, 2010, 116, 614-614.	0.6	8
170	Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission. Journal of Clinical Oncology, 2009, 27, 3987-3993.	0.8	48
171	Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 4585-4590.	0.8	258
172	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews, 2009, 23, 87-93.	2.8	35
173	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 2009, 27, 5720-5726.	0.8	155
174	The role of complete response in multiple myeloma. Blood, 2009, 114, 3139-3146.	0.6	206
175	The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents. Seminars in Hematology, 2009, 46, 127-132.	1.8	16
176	Multiple Myeloma in the Era of Novel Agents. Seminars in Hematology, 2009, 46, 107-109.	1.8	1
177	Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment.. Blood, 2009, 114, 1817-1817.	0.6	2
178	Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.. Blood, 2009, 114, 1818-1818.	0.6	10
179	Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. Blood, 2009, 114, 1876-1876.	0.6	4
180	High Complete and Very Good Partial Response Rates with Bortezomib+Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.. Blood, 2009, 114, 353-353.	0.6	20

#	ARTICLE	IF	CITATIONS
181	Bortezomib Plus Dexamethasone (VD) Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexamethasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. Blood, 2009, 114, 354-354.	0.6	15
182	Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).. Blood, 2009, 114, 529-529.	0.6	9
183	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	0.6	6
184	Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma.. Blood, 2009, 114, 957-957.	0.6	11
185	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood, 2009, 114, 1187-1187.	0.6	0
186	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.. Blood, 2009, 114, 3364-3364.	0.6	0
187	Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age.. Blood, 2009, 114, 2837-2837.	0.6	11
188	Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. Blood, 2009, 114, 874-874.	0.6	0
189	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Soci�t� Fran�saise de Greffe de Moelle et de Therapie Cellulaire. Experimental Hematology, 2008, 36, 535-544.	0.2	58
190	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, 2008, 112, 4445-4451.	0.6	164
191	Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2008, 26, 3183-3188.	0.8	73
192	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du My�lome. Journal of Clinical Oncology, 2008, 26, 4798-4805.	0.8	361
193	Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Soci�t� Fran�saise de Greffe de Mo�lle et de Therapie Cellulaire. Journal of Clinical Oncology, 2008, 26, 2264-2271.	0.8	284
194	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10�%549 patients from the International Myeloma Working Group. Blood, 2008, 111, 4039-4047.	0.6	190
195	Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood, 2008, 112, 3914-3915.	0.6	110
196	Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL. Blood, 2008, 112, 160-160.	0.6	8
197	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. Blood, 2008, 112, 3701-3701.	0.6	3
198	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. Blood, 2008, 112, 458-458.	0.6	0

#	ARTICLE	IF	CITATIONS
199	In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5. <i>Blood</i> , 2008, 112, 632-632.	0.6	0
200	Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome. <i>Blood</i> , 2008, 112, 2700-2700.	0.6	0
201	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. <i>Blood</i> , 2008, 112, 1309-1309.	0.6	0
202	Long-Term Follow-up Results of IFM9903 and IFM9904 Trials Comparing Non Myeloablative Allotransplantation with Autologous Transplantation in High-Risk De Novo Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1126-1126.	0.6	0
203	Stem Cell Transplantation in Multiple Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 311-316.	0.9	10
204	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , 2007, 92, 627-634.	1.7	83
205	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. <i>Blood</i> , 2007, 109, 3489-3495.	0.6	845
206	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. <i>Lancet, The</i> , 2007, 370, 1209-1218.	6.3	820
207	Role of autologous stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 747-759.	0.7	25
208	VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.. <i>Blood</i> , 2007, 110, 450-450.	0.6	51
209	High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients.. <i>Blood</i> , 2007, 110, 657-657.	0.6	0
210	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294.	0.6	639
211	Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. <i>Blood</i> , 2006, 107, 1292-1298.	0.6	174
212	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , 2006, 107, 397-403.	0.6	94
213	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , 2006, 107, 3474-3480.	0.6	344
214	Large-scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. <i>Transfusion</i> , 2006, 46, 1934-1942.	0.8	40
215	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. <i>British Journal of Haematology</i> , 2006, 135, 158-164.	1.2	155
216	The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials.. <i>Blood</i> , 2006, 108, 3077-3077.	0.6	20

#	ARTICLE	IF	CITATIONS
217	Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).. Blood, 2006, 108, 3551-3551.	0.6	13
218	Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.. Blood, 2006, 108, 3552-3552.	0.6	10
219	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. Blood, 2006, 108, 3554-3554.	0.6	14
220	Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLCL). A Retrospective Study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) Registry.. Blood, 2006, 108, 2946-2946.	0.6	0
221	Molecular Prognosis in Multiple Myeloma: The IFM Experience.. Blood, 2006, 108, 3491-3491.	0.6	1
222	Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 2006, 91, 1498-505.	1.7	233
223	One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology, 2005, 129, 403-410.	1.2	12
224	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. Journal of Clinical Oncology, 2005, 23, 7676-7684.	0.8	59
225	The Future Role of Thalidomide in Multiple Myeloma. Acta Haematologica, 2005, 114, 18-22.	0.7	4
226	Stem-cell transplantation in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 603-618.	0.7	21
227	Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma: Final Analysis of a Prospective Randomized Study of the "Inter-groupe Francophone du Myelome". Blood, 2005, 106, 1148-1148.	0.6	14
228	A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials.. Blood, 2005, 106, 622-622.	0.6	8
229	Stem Cell Factor (SCF) for Hematopoietic Stem Cell (HSC) Mobilization: Results of the Randomized IFM 99-01 Trial.. Blood, 2004, 104, 2921-2921.	0.6	2
230	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. Blood, 2004, 104, 747-747.	0.6	5
231	Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma. , 2004, , 159-182.		0
232	Autologous stem cell transplantation. , 2004, , 250-259.		0
233	A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.. Blood, 2004, 104, 5194-5194.	0.6	0
234	Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.. Blood, 2004, 104, 619-619.	0.6	11

#	ARTICLE	IF	CITATIONS
235	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2003, 349, 2495-2502.	13.9	938
236	Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 4284-4289.	0.6	306
237	High-dose therapy in multiple myeloma. <i>The Hematology Journal</i> , 2003, 4, 163-170.	2.0	12
238	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. <i>Blood</i> , 2002, 100, 3128-3134.	0.6	174
239	Comparison of 200 mg/m ² melphalan and 8 Gy total body irradiation plus 140 mg/m ² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. <i>Blood</i> , 2002, 99, 731-735.	0.6	531
240	The role of stem cell transplantation in multiple myeloma. <i>Blood Reviews</i> , 2002, 16, 245-253.	2.8	37
241	Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the intergroupe francophone du myélome (IFM). <i>The Hematology Journal</i> , 2002, 3, 185-192.	2.0	71
242	Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. <i>Blood</i> , 2001, 97, 3669-3671.	0.6	83
243	Randomized trial experience of the Intergroupe Francophone du Myélome. <i>Seminars in Hematology</i> , 2001, 38, 226-230.	1.8	44
244	Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2001, 19, 3340-3349.	0.8	87
245	Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. <i>British Journal of Haematology</i> , 2001, 114, 698-700.	1.2	22
246	Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Société Française de Greffe de Moelle. <i>Journal of Clinical Oncology</i> , 2000, 18, 537-537.	0.8	357
247	KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) IN BONE MARROW BIOPSY FROM PATIENTS WITH MULTIPLE MYELOMA: PCR AMPLIFICATION OF ORF26 BUT NOT ORF72 AND ORF75 SEQUENCES. <i>British Journal of Haematology</i> , 2000, 108, 197-198.	1.2	5
248	Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. <i>British Journal of Haematology</i> , 2000, 111, 292-302.	1.2	89
249	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 222-222.	0.8	147
250	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. <i>Blood</i> , 1999, 94, 1218-1225.	0.6	90
251	Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. <i>Lancet</i> , The, 1999, 354, 1092-1093.	6.3	159
252	Autologous peripheral blood progenitor cell transplantation for multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 171-191.	0.7	14

#	ARTICLE	IF	CITATIONS
253	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. <i>Blood</i> , 1999, 94, 1218-1225.	0.6	2
254	Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. <i>British Journal of Haematology</i> , 1998, 101, 766-769.	1.2	219
255	Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow biopsies of patients with Waldenstrom's macroglobulinaemia. <i>British Journal of Haematology</i> , 1998, 102, 795-797.	1.2	9
256	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 31, 343-349.	0.6	49
257	The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission. <i>Leukemia and Lymphoma</i> , 1997, 25, 469-478.	0.6	46
258	STANDARD THERAPY VERSUS AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 133-146.	0.9	41
259	A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 1996, 335, 91-97.	13.9	2,550
260	A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 21, 107-114.	0.6	15
261	Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. <i>British Journal of Haematology</i> , 1996, 94, 676-684.	1.2	23
262	Vincristine degradation by serum from leukemic patients: role of myeloperoxidase. <i>Leukemia and Lymphoma</i> , 1996, 20, 441-446.	0.6	9
263	Autologous BMT for Post-Remission Therapy in Adult ALL: An Immunological Approach. <i>Leukemia and Lymphoma</i> , 1994, 13, 95-98.	0.6	5
264	Hemolytic-Uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. <i>American Journal of Hematology</i> , 1994, 47, 254-255.	2.0	28
265	Epstein-Barr virus in familial Hodgkin's disease. <i>British Journal of Haematology</i> , 1994, 88, 636-638.	1.2	11
266	Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. <i>European Journal of Immunology</i> , 1993, 23, 820-824.	1.6	195
267	Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 379-384.	1.1	46
268	In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. <i>European Journal of Immunology</i> , 1991, 21, 1759-1762.	1.6	87
269	Association of the Philadelphia chromosome and 5q ⁻ in secondary blood disorder. <i>Cancer Genetics and Cytogenetics</i> , 1988, 30, 253-259.	1.0	16